New drug cocktail tested for ovarian cancer maintenance, but study stopped early
NCT ID NCT07000344
First seen May 02, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study looked at two drug combinations to keep ovarian cancer from coming back in patients whose cancer had responded to initial treatment. The plan was to enroll 70 people, but only 5 joined before the study was stopped. Participants took either three drugs (apatinib, fluzoparib, and letrozole) or two drugs (apatinib and letrozole) until their cancer worsened or side effects became too severe. The main goal was to see how many patients stayed cancer-free for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.